Patient
SITE001-0029
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE001 (USA) (Dr. Reyes)
consented 2025-09-21
Adverse events
8
Serious AEs
0
Open data queries
1
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 59); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-28 (study day 53); relationship: NOT RELATED
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 46); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-10 (study day 35); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-04-26 (study day 21); relationship: RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-25 (study day 20); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-04-24 (study day 19); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-08 (study day 3); relationship: not assessed
Data queries 1
EDC value 113 differs from the EHR: 131 mmHg (Observation/vs-7d2882169021-8480-6-20251011, 2025-10-11; EHR stated 131 mm[Hg]). Confirm against source and correct or explain.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.